There are 36.59 million Nigerians aged 15 years and older who are at risk of Cervical Cancer (CC) (1) . Annually 9, 922 women are diagnosed with the cancer and 8,030 die (2) many of these due to late presentation or suboptimal treatment. The high CC incidence of 16.7 per 100,000 women and Age Standardized incidence rate of 28.5% (3). Some studies gave incidence rates of 25-30 per 100,000 women (1). These figures are hospital based and are thus grossly underestimated. Cancer of cervix is now rightly considered a Sexually Transmitted Infection (STI) with Human Papilloma virus (HPV) as its cause; the evidence for this is overwhelming (4, 5) . HPV is the commonest viral STI affecting 660 million people globally (6) . It is the commonest STI in United States of America which also has one the most organized cervical cancer screening programs (7) . Nigeria has a high prevalence of STIs including HPV. HPV is widely spread in all states in Nigeria.
The overall prevalence of HPV in Ibadan [from Nigeria arm of International Agency Research in Cancer (IARC) study] was 26.3%; and 24.8% in women without cervical lesions (8) . The High risk HPV (HR-HPV) was predominant (19.7%) and was mostly due to viral types 16, 31, 35, 58. Low risk (LR-HPV) were found in 6.6% and mixed infections with more than one HPV type occurred in 33.5% of HPV positive cases. Although there was a small peak in women younger than 25 years, HPV prevalence remains persistently high in all age groups, Figure 1 (8, 9) . Also, HPV 16 appeared to a play a smaller role in CC in Nigeria than in Europe (10, 11) . A similar incidence of 21.6% was found in Okene, North-central Nigeria with HR-HPV prevalence of 16.6% and 3.5% having mixed infections (12) . (14), Speculoscopy and downstaging procedures can be promoted especially in rural areas.
The polyvalent and bivalent HPV vaccines are major tools for primary prevention. Although HPV vaccination is an attractive, cost-effective option, without international assistance with funding it will remain inaccessible to many Nigerian adolescents and youths. Meanwhile there is urgent need for baseline studies nationwide to determine the distribution pattern of prevalent HPV serotypes in a vast and diverse country like Nigeria. This will enable us know the applicability of the current bivalent Cervarix R (Glaxo 
